215 related articles for article (PubMed ID: 8783670)
41. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
Rosenman J
Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
[TBL] [Abstract][Full Text] [Related]
42. [Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Haie-Meder C; Fervers B; Chauvergne J; Fondrinier E; Lhommé C; Guastalla JP; Resbeut M
Bull Cancer; 1999 Oct; 86(10):829-41. PubMed ID: 10572234
[TBL] [Abstract][Full Text] [Related]
43. Phase II study of radiation therapy combined with weekly nedaplatin in locally advanced uterine cervical carcinoma: Kitasato Gynecologic Radiation Oncology Group (KGROG 0501).
Niibe Y; Hayakawa K; Tsunoda S; Kanai T; Imai M; Arai M; Arai T; Kawaguchi M; Jobo T; Hamada Y; Yago K; Unno N;
Jpn J Clin Oncol; 2007 Jan; 37(1):70-2. PubMed ID: 17204507
[TBL] [Abstract][Full Text] [Related]
44. Optimal management of locally advanced cervical carcinoma.
Keys H; Gibbons SK
J Natl Cancer Inst Monogr; 1996; (21):89-92. PubMed ID: 9023835
[TBL] [Abstract][Full Text] [Related]
45. The role of paclitaxel in the management of patients with carcinoma of the cervix.
Thigpen T; Vance R; Khansur T; Malamud F
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-41-S2-46. PubMed ID: 9045336
[TBL] [Abstract][Full Text] [Related]
46. Randomized comparison of fluorouracil plus cisplatin vs. cisplatin as an adjunct to radiation therapy in stage IIB-IVA squamous cell carcinoma of the cervix: pilot study.
Sukhaboon J; Porapakkhan P; Penpattanagul S
J Med Assoc Thai; 2009 Aug; 92(8):1072-6. PubMed ID: 19694333
[TBL] [Abstract][Full Text] [Related]
47. Cisplatin in advanced cancer of the cervix: an update.
Alberts DS; Garcia D; Mason-Liddil N
Semin Oncol; 1991 Feb; 18(1 Suppl 3):11-24. PubMed ID: 2003224
[TBL] [Abstract][Full Text] [Related]
48. Carcinoma of the uterine cervix: current status and future directions.
Thigpen T; Vance RB; Khansur T
Semin Oncol; 1994 Apr; 21(2 Suppl 2):43-54; quiz 55, 58. PubMed ID: 8202720
[TBL] [Abstract][Full Text] [Related]
49. The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review.
Small W
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):68-74. PubMed ID: 11917288
[TBL] [Abstract][Full Text] [Related]
50. Retrospective analysis of concomitant Cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: a gynecologic oncology group study.
Kunos C; Tian C; Waggoner S; Rose PG; Lanciano R
Int J Gynecol Cancer; 2009 Oct; 19(7):1258-63. PubMed ID: 19823064
[TBL] [Abstract][Full Text] [Related]
51. Guidelines for the administration of amifostine.
Schuchter LM
Semin Oncol; 1996 Aug; 23(4 Suppl 8):40-3. PubMed ID: 8783665
[TBL] [Abstract][Full Text] [Related]
52. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
53. Clinical study of radioprotective effects of amifostine (YM-08310, WR-2721) on long-term outcome for patients with cervical cancer.
Mitsuhashi N; Takahashi I; Takahashi M; Hayakawa K; Niibe H
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):407-11. PubMed ID: 8390418
[TBL] [Abstract][Full Text] [Related]
54. Recent developments in chemoradiotherapy for locally advanced cancer of the cervix.
Kim RY; Alvarez RD
Oncology (Williston Park); 2000 Sep; 14(9):1327-31, 1335; discussion 1336-8. PubMed ID: 11033830
[TBL] [Abstract][Full Text] [Related]
55. Topotecan in cervical cancer.
Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
[TBL] [Abstract][Full Text] [Related]
56. [An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
Niibe H; Takahashi I; Miyaishi K; Mitsuhashi N; Maehara Y; Nakajima N; Suto H; Saito Y; Yamakawa M; Sugiyama S
Nihon Gan Chiryo Gakkai Shi; 1985 Jun; 20(5):994-1001. PubMed ID: 2997352
[No Abstract] [Full Text] [Related]
57. Clinical status and optimal use of amifostine.
Capizzi RL
Oncology (Williston Park); 1999 Jan; 13(1):47-59; discussion 63, 67. PubMed ID: 10027198
[TBL] [Abstract][Full Text] [Related]
58. Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature.
Anders JC; Grigsby PW; Singh AK
Radiat Oncol; 2006 May; 1():14. PubMed ID: 16722547
[TBL] [Abstract][Full Text] [Related]
59. Chemoradiotherapy: the new standard care for invasive cervical cancer.
Rose PG
Drugs; 2000 Dec; 60(6):1239-44. PubMed ID: 11152009
[TBL] [Abstract][Full Text] [Related]
60. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
